Associated Papers
Molecular heterogeneity and measurable residual disease of rare NPM1 mutations in acute myeloid leukemia: a nationwide experience from the GBMHM study group.
Fournier E et al.
Leukemia, 2022
Analytical and Potential Clinical Performance of Oncomine Myeloid Research Assay for Myeloid Neoplasms.
Park J et al.
Molecular Diagnosis & Therapy, 2020
Identification of Circulating Genomic and Metabolic Biomarkers in Intrahepatic Cholangiocarcinoma.
Winter H et al.
Cancers, 2019
31795195 (PubMed )
Supplement: cancers-11-01895-s001.zip › ICC_ctDNA_Cancers_Supplementary_Table_5._50_cancer_gene_panel_information.xlsx › cms_106003
Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group.
Ferret Y et al.
Haematologica, 2018
29472349 (PubMed )
Supplement: 2017.183525.FERRET_SUPPL.pdf
Quantification of rare NPM1 mutation subtypes by digital PCR.
Bacher U et al.
British Journal of Haematology, 2014
Select a paper to view details